Literature DB >> 16341473

Lumping in pharmacokinetics.

Céline Brochot1, János Tóth, Frédéric Y Bois.   

Abstract

Pharmacokinetic (PK) models simplify biological complexity by dividing the body into interconnected compartments. The time course of the chemical's amount (or concentration) in each compartment is then expressed as a system of ordinary differential equations. The complexity of the resulting system of equations can rapidly increase if a precise description of the organism is needed. However, difficulties arise when the PK model contains more variables and parameters than comfortable for mathematical and computational treatment. To overcome such difficulties, mathematical lumping methods are new and powerful tools. Such methods aim at reducing a differential system by aggregating several variables into one. Typically, the lumped model is still a differential equation system, whose variables are interpretable in terms of variables of the original system. In practice, the reduced model is usually required to satisfy some constraints. For example, it may be necessary to keep state variables of interest for prediction unlumped. To accommodate such constraints, constrained lumping methods have are also available. After presenting the theory, we study, here, through practical examples, the potential of such methods in toxico/pharmacokinetics. As a tutorial, we first simplify a 2-compartment pharmacokinetic model by symbolic lumping. We then explore the reduction of a 6-compartment physiologically based pharmacokinetic model for 1,3-butadiene with numerical constrained lumping. The lumping methods presented here can be easily automated, and are applicable to first-order ordinary differential equation systems.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341473     DOI: 10.1007/s10928-005-0054-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Lumping of whole-body physiologically based pharmacokinetic models.

Authors:  I A Nestorov; L J Aarons; P A Arundel; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

2.  Genetic and dietary factors affecting human metabolism of 1,3-butadiene.

Authors:  T J Smith; Y S Lin; M Mezzetti; F Y Bois; K Kelsey; J Ibrahim
Journal:  Chem Biol Interact       Date:  2001-06-01       Impact factor: 5.192

3.  Optimal design for a study of butadiene toxicokinetics in humans.

Authors:  F Y Bois; T J Smith; A Gelman; H Y Chang; A E Smith
Journal:  Toxicol Sci       Date:  1999-06       Impact factor: 4.849

4.  PBPK modeling of complex hydrocarbon mixtures: gasoline.

Authors:  James E Dennison; Melvin E Andersen; Ivan D Dobrev; Moiz M Mumtaz; Raymond S H Yang
Journal:  Environ Toxicol Pharmacol       Date:  2004-03       Impact factor: 4.860

Review 5.  A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling.

Authors:  H J Verhaar; J R Morroni; K F Reardon; S M Hays; D P Gaver; R L Carpenter; R S Yang
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

6.  Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

7.  Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological, not biochemical, control.

Authors:  M C Kohn; R L Melnick
Journal:  Carcinogenesis       Date:  1993-04       Impact factor: 4.944

8.  Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach.

Authors:  James E Dennison; Melvin E Andersen; Raymond S H Yang
Journal:  Inhal Toxicol       Date:  2003-09       Impact factor: 2.724

  8 in total
  8 in total

1.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

2.  Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.

Authors:  Max von Kleist; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-25       Impact factor: 2.745

Review 3.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  A method for robust model order reduction in pharmacokinetics.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

5.  Understanding and reducing complex systems pharmacology models based on a novel input-response index.

Authors:  Jane Knöchel; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-14       Impact factor: 2.745

Review 6.  Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.

Authors:  Feras Khalil; Stephanie Läer
Journal:  J Biomed Biotechnol       Date:  2011-06-01

7.  Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data.

Authors:  A Gulati; G K Isbister; S B Duffull
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-08

8.  Model reduction in mathematical pharmacology : Integration, reduction and linking of PBPK and systems biology models.

Authors:  Thomas J Snowden; Piet H van der Graaf; Marcus J Tindall
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-26       Impact factor: 2.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.